Related Experiment Videos
Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to
M Chiariello1, M J Marinissen, J S Gutkind
1Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892-4330, USA.
Abstract:
The serine/threonine kinase Cot is a member of the mitogen-activated protein kinase (MAPK) kinase kinase family implicated in cellular transformation. Enhanced expression of this protein has been shown to activate both the MAPK and the c-Jun N-terminal kinase (JNK) pathways and to stimulate the nuclear factor of activated T cells and NF-kappaB-dependent transcription. However, the nature of the normal functions of the Cot protein and the molecular mechanisms responsible for its oncogenic potential are still largely unknown. Here, we show that overexpression of the cot proto-oncogene is sufficient to stimulate the expression of c-jun and that, in turn, the activity of c-Jun is required for Cot-induced transformation. These observations prompted us to explore the molecular events by which Cot regulates c-jun expression. We found that Cot potently stimulates the activity of the c-jun promoter utilizing JNK-dependent and -independent pathways, the latter involving two novel members of the MAPK family, p38gamma (ERK6) and ERK5. Molecularly, this activity was found to be dependent on the ability of Cot to activate, in vivo, members of each class of the MAPK kinase superfamily, including MEK, SEK, MKK6, and MEK5. Furthermore, the use of dominant interfering molecules revealed that Cot requires JNK, p38s, and ERK5 to stimulate the c-jun promoter fully and to induce neoplastic transformation. These findings indicate that Cot represents the first example of a serine/threonine kinase acting simultaneously on all known MAPK cascades. Moreover, these observations strongly suggest that the transforming ability of Cot results from the coordinated activation of these pathways, which ultimately converge on the regulation of the expression and activity of the product of the c-jun proto-oncogene.
Insights
The serine/threonine kinase Cot drives cellular transformation by activating multiple mitogen-activated protein kinase (MAPK) pathways. This activation stimulates c-Jun expression, a key factor in Cot-induced neoplastic transformation.
Area of Science:
- Cell Biology
- Molecular Oncology
- Signal Transduction
Background:
- The serine/threonine kinase Cot, a MAPK kinase kinase, is linked to cellular transformation.
- Its role in activating MAPK and JNK pathways, and influencing transcription factors like NF-kappaB, is known.
- However, Cot's normal functions and oncogenic mechanisms remain unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying Cot's oncogenic potential.
- To investigate how Cot regulates c-jun expression and its role in transformation.
- To identify the specific MAPK pathways involved in Cot-mediated cellular transformation.
Main Methods:
- Overexpression of the cot proto-oncogene in cellular models.
- Analysis of c-jun promoter activity and expression levels.
- Investigation of MAPK pathway activation (JNK, p38gamma/ERK6, ERK5) using dominant interfering molecules.
- Assessment of Cot's ability to activate MEK, SEK, MKK6, and MEK5.
Main Results:
- Cot overexpression is sufficient to induce c-jun expression, which is essential for Cot-driven transformation.
- Cot activates the c-jun promoter via JNK-dependent and -independent pathways.
- The JNK-independent pathway involves p38gamma (ERK6) and ERK5.
- Cot activates MEK, SEK, MKK6, and MEK5, indicating simultaneous action on all known MAPK cascades.
- JNK, p38s, and ERK5 are required for full c-jun promoter stimulation and neoplastic transformation.
Conclusions:
- Cot is a unique serine/threonine kinase that simultaneously targets all known MAPK cascades.
- Cot-induced neoplastic transformation results from the coordinated activation of these MAPK pathways.
- These pathways converge on regulating the expression and activity of c-Jun, a key proto-oncogene product.